Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F),...

Descripción completa

Detalles Bibliográficos
Autores principales: Pozniak, Anton, Arribas, Jose R., Gathe, Joseph, Gupta, Samir K., Post, Frank A., Bloch, Mark, Avihingsanon, Anchalee, Crofoot, Gordon, Benson, Paul, Lichtenstein, Kenneth, Ramgopal, Moti, Chetchotisakd, Ploenchan, Custodio, Joseph M., Abram, Michael E., Wei, Xuelian, Cheng, Andrew, McCallister, Scott, SenGupta, Devi, Fordyce, Marshall W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804743/
https://www.ncbi.nlm.nih.gov/pubmed/26627107
http://dx.doi.org/10.1097/QAI.0000000000000908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804743/
https://www.ncbi.nlm.nih.gov/pubmed/26627107
http://dx.doi.org/10.1097/QAI.0000000000000908

Ejemplares similares